Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2015

Xia Shu, Huang Chiang-Ching, Le Min, Dittmar Rachel, Du Meijun, Yuan Tiezheng, Guo Yongchen, Wang Yuan, Wang Xuexia, Tsai Susan, Suster Saul, Mackinnon Alexander C, Wang Liang

Abstract excerpt

OBJECTIVES: Cell free tumor DNA (cfDNA) circulating in blood has a great potential as biomarker for cancer clinical management. The objective of this study is to evaluate if cfDNA in blood plasma is detectable in early stage lung cancer patients. MATERIALS AND METHODS: We extracted cfDNAs and tumor tissue DNAs from 8 lung adenocarcinoma patients. We also extracted cfDNAs from 8 normal controls. To evaluate copy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to DNA Copy Number Variations

Share to DNA, Neoplasm

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasm Staging

Share to Plasma Cells

Source

Identifiers

PMID: 26233568
DOI: 10.1016/j.lungcan.2015.07.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.PMID 26233568Read ↗

Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.Semantic proximity Read ↗

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumSemantic proximity Read ↗

Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Bioinformatics Analysis for Circulating Cell-Free DNA in CancerSemantic proximity Read ↗

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002Semantic proximity Read ↗

Low-coverage whole-genome sequencing of plasma cell-free DNA to predict treatment response and progression-free survival in advanced NSCLC receiving EGFR-tyrosine kinase inhibitors or chemotherapy: A pilot prospective studySemantic proximity Read ↗

Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor.Semantic proximity Read ↗

Integrating genomic features for non-invasive early lung cancer detection.Semantic proximity Read ↗

Accurate Early Detection and EGFR Mutation Status Prediction of Lung Cancer Using Plasma cfDNA Coverage Patterns: A Proof-of-Concept Study.Semantic proximity Read ↗

Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.